Preventing seasonal influenza worldwide through vaccination, education, and international cooperation: research, findings, and recommendations from the Global Influenza Initiative by Paget, J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/153723
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Preventing seasonal influenza worldwide through
vaccination, education, and international cooperation:
research, findings, and recommendations from the Global
Influenza Initiative
John Paget
Netherlands Institute for Health Services Research, Utrecht, the Netherlands.
E-mail: j.paget@nivel.nl
Please cite this paper as: Paget. (2015) Preventing seasonal influenza worldwide through vaccination, education, and international cooperation: research,
findings, and recommendations from the Global Influenza Initiative. Influenza and Other Respiratory Viruses 9(Suppl. 1), 1–2.
This supplement to IORV, dedicated to the Global Influenza
Initiative (GII) and associated research, covers many of the
key challenges involved in influenza disease prevention,
management, and treatment. This supplement shares the
latest data and current thinking on a range of issues
including epidemiology and burden of disease, case defini-
tions, vaccination of pregnant women, and the potential
public health impact of quadrivalent influenza vaccines
(QIV) versus trivalent influenza vaccines (TIV).
The studies reported within this supplement have been
conducted by members of the GII, and the GII members have
utilized the group’s global reach to report on both expert
experience and the latest data from around the world.
In a report based on global surveillance data, Caini et al.
describe the epidemiologic characteristics of influenza A and
B epidemics. In this study, the authors obtained data from
the Northern and Southern hemispheres, including data
from tropical and subtropical regions. The authors also
examine the frequency of influenza B, the age distribution of
influenza B versus influenza A, the epidemiologic impact of
influenza B versus influenza A, and vaccine mismatches over
the past decade.
Cheng et al. present an important study on the burden of
influenza-associated deaths between 2002 and 2008 in the
Americas. This research examines whether influenza remains
an important cause of mortality in the Pan American Health
Organization region, and the outcome is clear.
As the detection and diagnosis of influenza is paramount,
Falsey et al. reviewed the currently used clinical case
definitions in the elderly population and report here their
findings regarding the different definitions and their respec-
tive sensitivity and specificity. The authors also suggest what
the case definition should include, and what the optimal
fever threshold should be to characterize influenza in the
elderly.
Vaccination of pregnant women continues to be the
subject of interest and debate, and additional data have
become available in recent years. Macias et al. undertook a
literature review, supplemented with data from GII mem-
bers, and have developed recommendations for the vaccina-
tion of pregnant women against seasonal influenza.
Finally, Crepey et al. used a dynamic model to estimate the
relative public health benefit of using QIV versus TIV for
routine influenza vaccination in the United States. An elegant
aspect of the authors’ analysis is that they have integrated the
potential cross-protection against a mismatched B lineage
conferred by the TIV, an important factor that potentially
limits the added value of QIV over TIV.
About the Global Influenza Initiative
Founded in 2012, the GII is a global expert scientific forum
chaired by Prof. Stanley Plotkin and composed of scientists,
researchers, and clinicians with expertise in epidemiology,
infectious diseases, immunology, and public health (see
http://www.globalinfluenzainitiative.org/). Our aim is to
strengthen and communicate scientific evidence on the
epidemiology and disease burden attributable to influenza.
Indeed, our mission is as follows:
1. To prevent seasonal influenza worldwide through vacci-
nation, education, and international cooperation, as
informed by virologic, epidemiologic, public health, and
health economic data.
2. As a priority, to establish the scientific evidence on the
worldwide burden of disease attributable to influenza and
to raise the profile of influenza as an important
preventable disease that warrants greater public health
attention and improved vaccination strategies.
3. To make recommendations on seasonal influenza
vaccine strategies, how influenza vaccines should be
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delivered, and which population cohorts should be
vaccinated.
The activities of the GII are supported by extensive data
compiled by national and hospital surveillance networks, in
addition to health economic modeling approaches. Critical
questions identified by the group are integrated into research
agendas that aim to address key knowledge gaps. GII activities
include steering committee meetings to define objectives and
agendas; roundtable meetings of all GII members, which meet
at approximately yearly intervals; and global dissemination of
recommendations and communications. Some GII members
are also part of the Global Influenza Hospital Surveillance
Network, which aims to improve understanding of global
influenza epidemiology and provide a framework for esti-
mating effectiveness of seasonal influenza vaccines in pre-
venting severe cases in various age and risk groups.
GII roundtable meetings have been held annually since
2012. The second GII roundtable meeting was held in July
2013, and the objective of the meeting was to review the latest
data on a variety of influenza-related clinical and scientific
subjects (such as the epidemiology of influenza, vaccine
effectiveness, and vaccination of special patient populations
such as pregnant women, patients with HIV, and healthcare
workers). There were more than 20 participants from 14
countries (Argentina, Brazil, Canada, China, theUnited States,
France, Italy, Mexico, the Netherlands, New Zealand, South
Africa, Spain, Turkey, and the United Kingdom). Based on
these latest data, the group developed the manuscripts
reported herein, and during the third GII roundtable meeting
(July 2014), the manuscripts were discussed, refined, and
updated with the latest data and expert opinion.
The GII works on an ongoing and committed basis to
develop materials and tools to assist in the prevention of
seasonal influenza, and introduce optimal vaccines and
vaccination strategies.
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